EA201891378A1 - Полициклические соединения в качестве ингибиторов тирозинкиназы брутона - Google Patents

Полициклические соединения в качестве ингибиторов тирозинкиназы брутона

Info

Publication number
EA201891378A1
EA201891378A1 EA201891378A EA201891378A EA201891378A1 EA 201891378 A1 EA201891378 A1 EA 201891378A1 EA 201891378 A EA201891378 A EA 201891378A EA 201891378 A EA201891378 A EA 201891378A EA 201891378 A1 EA201891378 A1 EA 201891378A1
Authority
EA
Eurasian Patent Office
Prior art keywords
brutton
polycyclic compounds
inhibitors
tyrosinkinase
tyrosinkinase inhibitors
Prior art date
Application number
EA201891378A
Other languages
English (en)
Other versions
EA035168B1 (ru
Inventor
Нидхи Арора
Дженесис М. Бакани
Джозеф Кент Барбей
Скотт Д. Бембенек
Минь Цай
Вэй Чэнь
Шарлотт Пули Декхат
Джеймс П. Эдвардс
Бахмананда Гхош
Кевин Кройттер
Ган Ли
Марк С. Тиченор
Дженнифер Д. Венэйбл
Дзяньмэй Вэй
Джон Дж. М. Винер
Яо У
Кунь Сяо
Фэйхуан Чжан
Яопин Чжу
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201891378A1 publication Critical patent/EA201891378A1/ru
Publication of EA035168B1 publication Critical patent/EA035168B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение направлено на соединения формулы (I) в качестве ингибиторов киназы Брутона и их получение, а также композиции, содержащие соединения формулы (I)
EA201891378A 2015-12-10 2016-12-09 Полициклические соединения в качестве ингибиторов тирозинкиназы брутона EA035168B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10
PCT/US2016/065954 WO2017100662A1 (en) 2015-12-10 2016-12-09 Polycyclic compounds as inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
EA201891378A1 true EA201891378A1 (ru) 2018-12-28
EA035168B1 EA035168B1 (ru) 2020-05-08

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891378A EA035168B1 (ru) 2015-12-10 2016-12-09 Полициклические соединения в качестве ингибиторов тирозинкиназы брутона

Country Status (29)

Country Link
US (4) US10717745B2 (ru)
EP (2) EP3386991B1 (ru)
JP (2) JP6835846B2 (ru)
KR (1) KR102103395B1 (ru)
CN (2) CN108884106A (ru)
AR (1) AR107042A1 (ru)
AU (1) AU2016366541B2 (ru)
BR (1) BR112018011526B1 (ru)
CA (1) CA3007990C (ru)
CY (1) CY1123263T1 (ru)
DK (1) DK3386991T3 (ru)
EA (1) EA035168B1 (ru)
ES (1) ES2805835T3 (ru)
HR (1) HRP20201193T1 (ru)
HU (1) HUE049502T2 (ru)
IL (1) IL259863B (ru)
JO (1) JO3794B1 (ru)
LT (1) LT3386991T (ru)
MA (2) MA53110A (ru)
MD (1) MD3386991T2 (ru)
ME (1) ME03803B (ru)
MX (1) MX2018007075A (ru)
PL (1) PL3386991T3 (ru)
PT (1) PT3386991T (ru)
RS (1) RS60604B1 (ru)
SI (1) SI3386991T1 (ru)
TW (1) TWI729047B (ru)
UY (1) UY37015A (ru)
WO (1) WO2017100662A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
EP4268898A3 (en) 2018-06-11 2024-01-17 Amgen Inc. Kras g12c inhibitors for treating cancer
EP4089095A4 (en) 2020-01-07 2024-03-27 Medshine Discovery Inc DEUTERATED THIENOPYRIDINE COMPOUND
BR112023017648A2 (pt) * 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
KR20240019214A (ko) 2021-06-04 2024-02-14 얀센 파마슈티카 엔브이 브루톤 티로신 키나제의 억제제 및 이의 사용 방법
EP4362947A1 (en) 2021-06-30 2024-05-08 Janssen Pharmaceutica NV Inhibitors of bruton's tyrosine kinase and methods of their use
AU2022326183A1 (en) 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
WO2023156599A1 (en) * 2022-02-18 2023-08-24 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
JP5305905B2 (ja) 2005-08-08 2013-10-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリミジンキナーゼ阻害剤
WO2007092879A2 (en) * 2006-02-08 2007-08-16 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
DK2081435T3 (en) 2006-09-22 2016-08-15 Pharmacyclics Llc INHIBITORS OF BRUTON'S TYROSINKINASE
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
JP5739334B2 (ja) 2009-08-26 2015-06-24 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
SG10201809696UA (en) 2013-03-15 2018-11-29 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
KR102413253B1 (ko) * 2013-12-11 2022-06-27 바이오젠 엠에이 인코포레이티드 종양, 신경 및 면역에서 인간 질환을 치료하는데 유용한 바이아릴 화합물
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
KR20180093974A (ko) 2018-08-22
HRP20201193T1 (hr) 2020-11-13
TWI729047B (zh) 2021-06-01
HUE049502T2 (hu) 2020-09-28
CN113121562A (zh) 2021-07-16
EP3386991B1 (en) 2020-06-03
KR102103395B1 (ko) 2020-04-23
MA53110A (fr) 2021-05-12
JO3794B1 (ar) 2021-01-31
ME03803B (me) 2021-04-20
CA3007990C (en) 2024-01-02
EA035168B1 (ru) 2020-05-08
PT3386991T (pt) 2020-08-18
US20190276471A1 (en) 2019-09-12
IL259863B (en) 2020-06-30
CN108884106A (zh) 2018-11-23
JP7072690B2 (ja) 2022-05-20
UY37015A (es) 2017-06-30
AU2016366541B2 (en) 2021-05-13
SI3386991T1 (sl) 2020-08-31
CY1123263T1 (el) 2021-12-31
JP2021073286A (ja) 2021-05-13
TW201734021A (zh) 2017-10-01
BR112018011526A2 (pt) 2018-11-21
US10934310B2 (en) 2021-03-02
CN113121562B (zh) 2022-09-13
MA43409B1 (fr) 2020-10-28
IL259863A (en) 2018-07-31
US20210101910A1 (en) 2021-04-08
BR112018011526B1 (pt) 2024-02-27
ES2805835T3 (es) 2021-02-15
RS60604B1 (sr) 2020-08-31
US10717745B2 (en) 2020-07-21
DK3386991T3 (da) 2020-07-13
MD3386991T2 (ro) 2020-11-30
EP3386991A1 (en) 2018-10-17
LT3386991T (lt) 2020-08-25
NZ742484A (en) 2021-09-24
WO2017100662A1 (en) 2017-06-15
US11319329B2 (en) 2022-05-03
US20230097422A1 (en) 2023-03-30
EP3719022A1 (en) 2020-10-07
CA3007990A1 (en) 2017-06-15
JP2018536686A (ja) 2018-12-13
MX2018007075A (es) 2018-11-09
PL3386991T3 (pl) 2021-03-08
US20170283430A1 (en) 2017-10-05
JP6835846B2 (ja) 2021-02-24
AR107042A1 (es) 2018-03-14
AU2016366541A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
EA201891378A1 (ru) Полициклические соединения в качестве ингибиторов тирозинкиназы брутона
CL2017000786A1 (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
PH12017501817A1 (en) Heterocyclic compounds as lsd1 inhibitors
EA201991183A1 (ru) Новые ингибиторы глутаминазы
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
EA201891379A1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
EA201991198A1 (ru) АМИНОТИАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ c-Kit
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201892147A1 (ru) Бициклические соединения
EA201790781A3 (ru) Противовирусные соединения
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
EA201491579A1 (ru) Соединения оксазолидин-2-она и их применения в качестве ингибиторов pi3k
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201500653A1 (ru) Композиции, содержащие триазольное соединение
EA201492002A1 (ru) Противовирусные соединения
EA201890333A1 (ru) Противовирусные соединения
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201690844A1 (ru) Ингибиторы gsk-3
EA201790570A1 (ru) Модуляторы р2х7
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения